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Recent advances in synthetic methodologies have brought us closer than ever to the precision
conferred by nature. For example, the control possible in reversible deactivation radical
polymerization enables us to design and synthesize macromolecules with unprecedented
control over not only the polymer chain ends, but also the side chain functionality. Furthermore,
this functionality can be exploited to afford chemical modification of peptides and proteins,
with ever-improving site-specificity, yielding a range of well-defined protein/peptide-hybrid
materials. Such materials benefit from the amalgamation of the properties of proteins/peptides
with those of the synthetic (macro)molecules in question. Here, the latest developments in the
synthesis of functional polymers and their use for preparation of well-defined protein/peptide-
polymer conjugates will be discussed, with particular attention focused on modulating the
stability, efficacy and/or administration of therapeutic peptides.
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1. Introduction
Nature exploits complex intracellular machinery to control macromolecular precision and
functionality. From mRNA transcription in the nucleus to translation in the ribosome, the
primary sequence of amino acids is exquisitely and reproducibly controlled throughout the
lifetime of the cell. Enzymatically-mediated, post-translational modifications can also take
place which can expand the structural and functional diversity of proteins through precise
modification of amino acid residues.[1]
A great deal of work has been conducted towards replicating the precision of nature in the
laboratory. The development of synthetic methods that enable the production of
macromolecules of equal precision and chain-length homology has become the nexus of some
synthetic polymer scientists.[2] In step-growth polymerization efforts have been made to
prepare monomers capable of undergoing high yielding, chemo- and regiospecific coupling
reactions in the presence of orthogonal and/or protected functionality that can support further
chain growth.[3, 4] In this way, discrete oligomeric molecules have been realized, but the
multistep, stepwise nature of the syntheses is disadvantageous for the preparation of higher
molecular weight species and higher order structures. To address this a number of ionic and
radical chain-growth polymerizations have been developed with particular focus on optimizing
the level of ‘livingness’ retained throughout the polymerization reaction. Reversible-
deactivation radical polymerization (RDRP) is generally not as well controlled as ionic,
particularly anionic, polymerizations, however it is much more robust and ‘user-friendly’ from
a synthetic point view. Perfect sequence control requires sequential, iterative additions of single
monomer units to every growing chain. To this end, single monomer addition has been
demonstrated[5, 6] but radical reactivity precludes sequential single monomer addition, and
therefore alternative approaches including kinetic control,[7, 8] solution[9, 10] and segregated
templating[11] have also been investigated.
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In the absence of nature’s innate precision, specific chemical modification of proteins/peptides
with (macro)molecules, referred to as bioconjugation,[12] can be challenging due the array of
diverse functionality present in protein/peptide structures. Generally, modification is either
achieved by targeting the intrinsic functionality presented by natural amino acid residues, or by
extrinsic manipulation of the functionality present via (bio)chemical intervention, typically
through mutation during protein expression or peptide synthesis, to introduced unnatural amino
acid residues with specific and orthogonal functionality.[13] The latter confers enhanced
specificity through the use of conjugating groups that contain the complimentary functionality,
but can be time consuming, low yielding and compromise protein/peptide activity
irrecoverably. Consequently, enhancing the site-specificity of chemical reactions that target
natural amino acids is a much more attractive approach.
This talent article will offer a brief insight into the latest radical polymerization protocols
developed for the synthesis of polymers with optimal control over the molecular weight
distribution and functionality under biologically relevant conditions. Greater attention will be
paid to the use of these polymers, and other (macro)molecules, for the modification of proteins
and peptides. From well-established protocols, to novel methods that enhance site specificity,
the influence on structure, function and activity will be considered with specific biological,
medicinal or pharmaceutical applications in mind.
2. 'Precision' polymerisation using aqueous RDRP
The activation-deactivation equilibrium associated with RDRP protocols, such as Cu-mediated
radical polymerizations; atom-transfer radical polymerization (ATRP),[14] single electron
transfer living radical polymerization (SET-LRP);[15] reversible addition fragmentation chain-
transfer polymerization (RAFT)[16] and nitroxide-mediated polymerization (NMP),[17] lends
itself to manipulation to afford unprecedented control over the activation-deactivation
equilibrium and therefore the radical concentration. Consequently, termination events can be
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minimized resulting in exceptional control over the molecular weight, molecular weight
distribution (dispersity, Ɖ) and chain-end functionality up to quantitative conversions. Re-
initiation with sequential addition of alternative monomers can lead to the formation of multi-
block copolymers with complex compositions in which the side chain functionality is not
perfectly, but discretely distributed throughout each polymer chain.[18-21] The most recent
advances in Cu-mediated RDRP have centred on retaining this control over polymerisation in
aqueous and biologically relevent media and using external stimuli to control the activation-
deactivation equilibrium (Figure 1).[22, 23]
Insert Figure 1 here
Historically, performing ATRP in aqueous solution has proved challenging owing to an
increase in the activation-deactivation equilibrium constant (KATRP), enhanced rates of
propagation (kp) and the susceptibility of the CuIX/L complex (X = Br, Cl; L = amine ligand)
to undergo CuI-X bond dissociation. Moreover, CuIX/L complexes undergo rapid and complete
disproportionation in pure aqueous solutions forming elemental Cu0 and CuIIX2/L.
In 2013,[24] this was exploited for the development of aqueous SET-LRP which employs Cu0
as the activating species and CuIIX2/L as the deactivating species. Using N-isopropylacrylamide
(NIPAM) as a model monomer reaction conditions were optimized with respect to the [CuIX] :
[L] ratio as well as the reaction temperature, concentration and time to access a broad range of
molecular weights (Figure 2).
Insert Figure 2 here
Subsequently, a variety of hydrophilic (meth)acrylate and acrylamide monomers have been
shown to be compatible with the polymerization system from acrylamide[25] to functional
monomers including; acryloylmorpholine,[26] oligo(ethylene glycol) methyl ether
(meth)acrylate (OEG[M]A),[24] unprotected glycomonomers,[27] 2-acrylamido-2-
methylpropane sulfonic acid sodium salt (NaAMPS) and zwitterionic acryloyl
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phosphatidylcholine (APC).[28] The polymerization is also robust to deviations in the aqueous
solvent composition, with controlled polymerization possible in buffer solutions,[24] complex
alcoholic solutions,[29] carbonated water[30] and most significantly, blood serum.[31]
One potential limitation of the aqueous system is hydrolysis of the ω-Br chain end of the target
poly(acrylates/acrylamides), which was identified as a deleterious side reaction prior to, and
during, the initial investigation.[32] To circumvent this, kinetic and mechanistic investigations
were conducted to establish optimal reaction conditions to enable the formation of complex
(multi)block copolymers via sequential monomer addition in pure aqueous media.[33, 34]
Structural diversity and complexity can also be introduced through changes in the target
polymer architecture. As well as simple linear polymers, telechelic homopolymers and (multi)
block polymers have also been prepared.[35-37] Furthermore, Qiao and Becer have independently
adopted the rapid, robust and benign conditions of the aqueous SET-LRP system for the
synthesis of star polymers, which are opportunistic for use as unimolecular nanoparticles in
biomedical applications, via arm-first and core-first approaches respectively.[38, 39] The work of
Becer et al has expanded the complexity further through the synthesis of a 3-arm star pentablock
copolymer with excellent control over the molecular weight distribution (Ɖ < 1.14).
Double hydrophilic block copolymers composed of short glycomonomer[27] or
phosphatidylcholine[28] blocks, chain extended in situ with a longer thermoresponsive monomer
blocks have also been prepared by aqueous SET-LRP. Upon heating above the lower critical
solution temperature (LCST), the diblock copolymers self-assemble into polymer nanoparticles
with good polydispersity indices, within the micellar size range (~ 30 nm, PDI < 0.12) (Figure
3).
Insert figure 3 here
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3. Synthetic approaches to covalently-linked protein/peptide-polymer
conjugates
Bio(macro)molecules such as proteins, peptides, nucleic acids, etc. are inherently bioactive,
serving as therapeutics, specific ligands for cellular receptors and sources of genetic
information. However, they often exhibit poor bioavailablity, can be highly immunogenic and
rapidly cleared by the reticuloendethial system (RES) resulting in short plasma half-lives in
their native forms. A popular approach to address this is the attachment of synthetic polymers
to form bio(macro)molecule-polymer conjugates that synergistically combine the properties of
the individual components to suit a particular application.[40] This was originally achieved using
poly(ethylene glycol) i.e. PEGylation,[41] which upon conjugation to therapeutic proteins has
been shown to increase bioavailablity and plasma half-life, whilst reducing immunogenicity
and proteolysis. A number of peglyated protein therapeutics have been granted FDA approval
and made it to the market, with several others demonstrating clinic potential.[42]
In light of the advances made by the latest ring opening polymerization ([C]ROP, ROMP) and
RDRP (ATRP, SET-LRP, RAFT, NMP) protocols, such polymers are ideal candidates for post-
polymerization modification and protein/peptide modification via ‘grafting-to,’ ‘grafting-
from,’ and ‘grafting-through’ techniques which can be acheieved via covalent or non-covalent
intereactions. ROP of N-carboxyanhydrides has been developed whereby functionality for site-
specific protein ligation can be topologically installed in situ.[43] Cationic ROP of oxazolines
can be terminated using functional nucleophilies, and the resulting polymers have been
‘grafted-to’ proteins.[44] Furthermore, side chain functionality, incorporated either in the
oxazoline monomer or through post-polymerization has been exploited for the ‘grafting-
through’ modification of polymer chains[45] and particles.[46] The latest generation of the
Grubb’s catalyst has also led to the use of ROMP in the preparation of protein-polymer
conjugates via both ‘grafting-to’ and ‘grafting-from’ strategies.[47, 48] The resulting polymers
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composed of norbornene-based monomers exhibit markedly different properties compared to
the conventional (meth)acrylate derived polymers traditionally employed.
The modification of proteins/peptides with polymers prepared by RDRP is perhaps the most
well studied and understood approach. Futhermore the precision conferred by RDRP enables
the composition of synthetic (co)polymers to be manipulated to ellicit additional properties to
bestow of target biomolecules such as stimulated responsivity,[49] usually via phase transition
to fluctuations in temperature, pH and redox, all of which are associated with the
microenvironment of stressed, diseased or malignant tissues and cells.
3.1 Covalent modification
The (ir)reversible, covalent attachment of polymers to protein/peptides is the most common
approach to modification. Chain-end and side-chain functionality can be specifically
incorporated to compliment the functionality presented by amino acid residues leading to
conjugation via ‘grafting-to’ and ‘grafting-through’ methods respectively. Alternatively,
proteins/peptides can be modified to include functional groups capable of (re-)initiating radical
polymerization such as α-halo esters for Cu-mediated polymerization, or thiocarbonylthio
groups for RAFT in a ‘grafting-from’ approach.
3.1.1. ‘Grafting-to’
The grafting of polymer chains to a protein/peptide is a stepwise process wherein the polymer
is initially synthesized with high α- and ω-chain end fidelity, before conjugation through one,
or both, chains ends to target proteins/peptides through reaction at functional amino acid
residues. Nucleophilic amines present at the N-terminus and in the side chain of lysine residues
are attractive targets due their relatively high natural abundance and exposure at protein
surfaces.[50, 51] They are reactive towards functional groups such as; carboxylic acids,[52] through
carbodiimide coupling; activated esters (e.g. NHS-ester,[53] pentafluorophenol ester,[54] etc.) or
thiazoline-2-thione groups,[55] through nucleophilic substitution; isocyanates,[56] by
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nucleophilic addition; and aldehydes,[57] via reversible imine formation which can be
subsequently reduced to yield secondary amines. More recently, polymers synthesized using
squaric acid ester amide functional initiators[58] or CTAs[59] have been employed for amine-
targeted bioconjugation, proving to be less prone to hydrolysis than activated ester analogues,
leading to greater grafting efficiencies. NMP has been applied less frequently compared to
RAFT, ATRP and SET-LRP. However functional SG1 alkoxyamines have been developed to
install suitable chain-end functionality and enable conjugation to both proteins[60] and drugs.[61]
The relatively high natural abundance of amine-functional groups can also be disadvantageous,
leading to heterogeneous products due to the addition of multiple polymer chains to target
proteins/peptides, which itself is implicated in reduction or complete loss of bioactivity.
Consequently, less abundant residues such as tyrosine[62] and tryptophan[63] have been targeted
for modification through their electron-rich aromatic side chains. However these residues are
often located in poorly accessible hydrophobic domains of larger proteins and require the use
of elaborate functional linkers.
The pendent thiol group of cysteine residues is a much more attractive target for site-specific
modification of proteins/peptides owing to its relatively low natural abundance and soft
nucleophilic character. Thiol groups readily undergo disulfide bond metathesis with pyridyl
disulfide functional polymers to form reductively labile protein/peptide conjugates.[64]
Alternatively, nucleophilic substitution (α-halocarbonyls) or addition (α,β-unsaturated esters,
maleimides, vinyl sulfones)[65] reactions proceed with good selectivity to furnish less labile
thio-ether linked conjugates. Free thiol groups are prone to oxidation, and often exist as inter-
or intramolecular disulfides, the stability of which is naturally controlled by the local redox
environment. Chemically, reduction can be afforded using reducing agents such as phosphines,
hydrazine and zinc, to yield free thiols, or thiolate anions that readily react with the reagents
listed above. However, the existence of disulfide bonds between proximal cysteine residues
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contributes to the tertiary and/or quaternary structure of proteins. Therefore, depending on their
location, they are often crucial for maintaining structure or activity, both of which can be
compromised upon disulfide bond reduction. As such reagents capable of re-bridging accessible
disulfides are opportunistic for enhancing site-specificity with minimal disruption to the native
protein structure and activity (Figure 4).
Insert figure 4 here
Weil et al.[66] have comprehensively reviewed and compared the known methods for disulfide
bond modification as a route to forming protein, peptide and antibody-hybrid materials. The
pioneering work of Brocchini et al.,[67] who employed bis-sulfone functional PEG to modify
immunotherapeutic protein interferon, was followed by contributions from the groups and
Caddick and Baker, who introduced mono-substituted (MSM)[68] and di-substituted maleimide
(DSM)[69] derivatives as irreversible and reversible linkers respectively. More recently, Caddick
et al. have also employed dibromopyridazinediones[70] which have two additional sites for
functionalization, conferring homo- or hetero-bifunctional modification, and alkyne reagents[71]
have been employed for radical thiol-yne chemistry at reduced disulfides. Haddleton, Davis and
Wilson, have combined the efficiency of the DSM chemistry with the precision of RDRP and
also introduced organic arsenicals as benign alternatives to DSM’s, exhibiting comparable
conjugation efficiency, reversibility and enhanced specificity.
Having demonstrated the potential of DSMs for protein modification, Caddick and Baker were
the first to exploit their reactivity for PEGylation.[69] DSM-PEG was prepared and conjugated
to somatostatin within 30 minutes and a cell based assay demonstrated that the conjugates
retained the agonist activity of native somatostatin against a somatostatin receptor (SSTR2).
This was then expanded to afford simultaneous PEGylation and fluorescent labelling of
peptides using salmon calcitonin (sCT)[72] as a model peptide with the DSM moiety acting as
both the conjugation linker and the fluorophore in the process referred to as conjugation-
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induced fluorescence (Figure 5). The fluorescent properties of the DSM-linked conjugates is an
attractive alternative to conventional protein/polymer-labelling which often requires
incorporation of bulky, planar fluorophores that can alter solution properties.
Insert figure 5 here
Polymeric DSMs were initially prepared by ATRP, first in a sequential reaction whereby
dibromomaleimide (DBM) was added to the α-terminus of POEGMA in a post-polymerisation
modification.[73] This was necessary due to the DBM functional group severely retarding the
rate of ATRP, which was circumvented by employing a dithiophenolmaleimide (DTM) initiator
capable of directly synthesizing DTM-POEGMA for subsequent conjugation.[74] Conjugation
was shown to proceed rapidly, within 15 minutes, and stoichiometrically which alleviates the
need for large excesses of polymer and extensive purification following conjugation. RAFT,[75]
ring opening polymerization (ROP)[72] and aqueous SET-LRP[76] have also exhibited
compatibility for the DSM functional group during the synthesis of DSM-functional polymers.
Arsenic (As) exists as a dichotomous enigma between toxicity and therapy in (bio)chemistry
and medicine. It can exist in a number of oxidation states with AsIII and AsV considered as
‘biologically relevant.’ The reactivity of arsenic towards thiols in each oxidation state is discrete
and distinctive. In the presence of thiols, AsV readily undergoes two electron reduction to AsIII
which dominates the therapeutic and toxic potential of arsenic due to its high affinity for thiols,
readily forming As-S covalent bonds, which is not possible for AsV. Mono-thiol adducts are
prone to hydrolysis and subsequent re-oxidation (to AsV), however the affinity and stability is
markedly enhanced for chelating vicinal or neighbours-through-space (proximal) dithiols, such
as those presented by naturally occurring disulfide bonds.[77] This was exploited using a reduced
derivative of p-arsanilic acid, which was initially shown to rapidly and stoichiometrically re-
bridge the disulfide of sCT (Cys1-Cys7).[78] To explore the specificity for re-bridging disulfide
bonds, native and reduced bovine serum albumin (BSA/rBSA) were employed as model
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proteins containing a single thiol group in the absence and presence of an accessible, reduced
disulfide respectively. Using Ellman’s assay, AsIII was qualitatively shown to react with the
proximal dithiols derived from the reduced disulfide but did not react with the remaining mono-
thiol group (Cys34) (Figure 6). Alternative thiol and disulfide reactive reagents containing
maleimide and DSM functional groups were shown to react indiscriminately with all available
thiol groups.
Insert figure 6 here
Polymeric arsenicals were synthesized by Cu0-mediated RDRP in aqueous solution (aqueous
SET-LRP) using a novel AsV-functional initiator to ensure the presence of a single AsV-group
at each α-chain end. AsV-poly(oligo[ethylene glycol methyl ether acrylate]) (AsV-POEGA) was
shown to be non-toxic to a variety of cell lines, relative to non-functional controls, and was
readily converted to AsIII-POEGA, upon reduction with an excess of the glutathione.
Conjugation to sCT (Figure 6) was achieved quantitatively (w.r.t. peptide) and confirmed by
RP-HPLC, verified by quantitative release of native and reduced sCT from the conjugate upon
addition of stronger chelating dithiols such as ethanedithiol or reduced lipoic acid.
3.1.2. ‘Grafting-through’
Where the use of functional initiators and CTAs installs appropriate functionality at the polymer
chain ends, the incorporation of functional monomers into the polymer composition can
facilitate the attachment of multiple bioactive molecules in a ‘grafting-through’ process. This
is an attractive method for increasing the grafting density and concentration of small bioactive
molecules such as mono- and oligosaccharides,[79] peptides[80] and nucleic acids,[81] and has also
been applied to larger antibody fragment proteins.[82] The level of control associated with RDRP
allows mono or multifunctional scaffolds to be prepared that can be modified post-
polymerization to afford conjugation. A plethora of monomers have been synthesized
containing desirable functionality including; alkyne, epoxide, aldehyde/ketone, azlactone
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hydrazyl, oxime or activated ester side chains, all capable of facile ‘click’-like modifications.[83-
88]
More recently, an acrylate monomer containing a thiol reactive DSM pendant group was
prepared and copolymerized (0 – 10 mol%) with thermoresponsive monomer triethylene glycol
methyl ether acrylate (TEGA) by Cu0-wire mediated polymerization in DMSO (Mn ≈ 10000 
g.mol-1, Ɖ < 1.25).[89] Having previously exploited the reactivity of DSMs at polymer chain
ends for disulfide bond conjugation, monothiol reagents were employed in this case to
quantitatively and reversibly modify the polymers. Tripeptide GSH and thio-glucose were
employed as peptide and monosaccharide models. Successful conjugation was confirmed by
DOSY NMR, SEC, changes in the cloud point temperature and, in the case of thio-glucose, an
unexpected and as yet unexplained change in the fluorescence properties of the polymer,
whereby fluorescence is quenched upon conjugation of the sugar moiety.
3.1.3. ‘Grafting-from’
Historically, large stoichiometric excesses of functional polymers were required to achieve
acceptable conjugation yields in the ‘grafting-to’ approach, presumably due to the steric
hindrance associated with bringing together large synthetic and biological macromolecules.
This in turn, imposes the need for an exhaustive purification step in any conjugation protocol
in order to ultimately obtain pure protein/peptide-polymer conjugate material. The efficiency
of the latest ‘grafting-to’ technologies, and systematic studies on the effect of linker length on
conjugation yields go some way to addressing some of these limitations. As an alternative
approach to protein/peptide conjugation, ‘grafting-from’ methods require the modification of
the protein/peptide with a group capable of mediating radical polymerization e.g. initiators,[90]
CTAs,[91] prior to polymerization, which can then proceed directly from the protein/peptide.
This can markedly improve product homogeneity and alleviate the need for extensive
purification as large conjugates are routinely separable from any remaining smaller molecules
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such as unreacted monomers. On the other hand, the use of protein/peptide macroinitiators
engenders the need for mild reaction conditions, particularly with respect to solvent and
temperature which can compromise bioactivity following periods of prolonged exposure.
Furthermore, due to limitations in the quantities of macroinitiator the polymerization should
also be controlled and efficient at low concentrations and the protein/peptide should be
compatible with chosen catalyst system.
To meet these requirements, the aqueous SET-LRP protocol described above was
adventitiously discovered whilst optimizing reaction conditions that could facilitate Cu-
mediated polymerization from biological macroinitiators. This technique was then adapted and
employed for polymerization from a variety of proteins/peptides ranging from small therapeutic
peptides (sCT, bovine insulin), to larger enzymes (lysozyme) and globular proteins (BSA,
bovine haemoglobin, Hb), all of which were readily transformed into macroinitiators using
simple NHS-ester and NHS-carbonate functional initiators (Figure 7).[92] The NHS-ester
initiator reacts with the N-terminus and ω-NH2 of accessible lysine residues to form irreversible
amide initiators whereas the NHS-carbonate can react with the same residues to form carbamate
linkages, which could be subsequently cleaved under relatively mild conditions. The integrity
of the polymerization taking place from the protein/peptides was then determined by standard
solution characterization of the cleaved, ‘grafted-from’ polymer chains using NMR, SEC, IR,
MALDI-ToF-MS.
Insert figure 7 here
Interestingly, upon modification to form the macroinitiators, the proteins/peptides exhibited
variable solution properties. Soluble BSA macroinitiator, containing an average of 29 initiating
groups, according to MALDI-ToF-MS, was used for the polymerization of dimethylacrylamide
(DMA), NIPAM and OEGA to form conjugates which were characterized by SDS-PAGE and
SEC. Cleavage of the polymer chains from proteins revealed that controlled polymerization
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took place from each initiating site furnishing polymers with relatively narrow dispersities (Ɖ
< 1.30). Polymerization from the Hb macroinitiator (~12 initiating sites) was less controlled
upon analysis of the cleaved polymers (Ɖ = 1.68, NIPAM; Ɖ = 1.62, OEGA). This was
attributed to the presence of the heme groups, which themselves have been shown to mediate
AGET-ATRP,[93] which can interact with the CuII[94] present in the aqueous SET-LRP system,
sequestering it from solution leading to poorer control and broader dispersities.
Lysozyme and sCT were found to be insoluble in water upon conversion to their macroinitiator
analogues containing ~5 and ~2 initiating sites respectively. However they were both readily
dispersed in 0.5% aqueous solutions of sodium dodecyl sulfate (SDS). Under standard aqueous
SET-LRP conditions, polymerization of NIPAM and OEGA from these dispersed
macroinitiators was not well controlled (Ɖ > 1.99). Poor control over polymerization had
previously been reported during ATRP in emulsion using anionic surfactants which were
implicated in the loss of halide ions from the solutions.[95] This causes an unfavourable
imbalance in the activation-deactivation equilibrium which can be countered by the addition of
NaBr to the surfactant solution. In the presence of an excess of NaBr, control over the
polymerization of NIPAM was shown to be much improved from both lysozyme and sCT
macroinitiators (Ɖ < 1.25).
Insulin derived macroinitiators (1-3 initiating groups) were found to form stable colloidal
solutions of polydisperse, irregular shaped particles (30-200 nm, TEM) at neutral pH. Surface
initiated SET-LRP has previously be demonstrated using dispersed latex particles,
functionalized with initiating groups, via Cu0-wire mediated polymerization in water.[96] With
this in mind, it was hypothesized that the aqueous SET-LRP system could mediated
polymerization from the colloidal insulin particles dispersed in water. Polymerization of
NIPAM yielded a conjugate with a relatively narrow dispersity (Mn = 42900 g.mol-1, Ɖ < 1.28).
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Cleavage of the polymer chains revealed well controlled PNIPAM with narrow dispersities (Mn
= 14500 g.mol-1, Ɖ < 1.16).
3.2 Non-covalent modification
In the field of dynamic, tunable and responsive polymers/materials, non-covalent interactions
play an ever increasing role. With respect to non-covalent protein/peptide-polymer
conjugations, modification is possible via high avidity interactions between proteins and natural
and/or synthetic ligands incorporated into polymer compositions. Examples of natural
ligands[97] include cofactors for enzyme reconstitution,[98] sugars[99] and biotin[100] that have
high affinity interactions with lectins and streptavidin respectively. Alternatively, synthetic
ligands have been designed that exploit electrostatic interactions,[101] metal-ligand affinity[102]
and host guest interactions[103] to couple proteins/peptides and polymers. Finally,
proteins/peptides can be incorporated into polymer gel matrices, either as non-covalent cross-
linking groups (e.g. antibody-antigen interactions)[104] or as encapsulants,[105] both which have
great potential as biological-stimuli responsive materials.
Glycopolymers can serve at synthetic analogues for natural oligo/polymersaccharides and
complex glycoproteins that have naturally high affinity for specific lectin proteins. Recently,
non-covalent PEGylation was demonstrated using hexavalent lectin RSL, derived from
Ralstonia solanacearum and fucose-capped PEG as the complementary monosaccharide
ligand.[106] The affinity of sugar-lectin interactions is often enhanced by multivalent sugar
ligands that can complement the valency of the target lectin.[107] The synthesis of simple
oligosaccharides is time and resource consuming, and is limited to small scales. Conversely,
RDRP facilitates the synthesis of glycopolymers and the composition and high-order
architecture or morphology can be intricately controlled. The composition can be varied using
either synthetic vinylic glycomonomers or by using functional monomers that can be
subsequently modified, post-polymerisation by functional glycosides. Homopolymers and
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sequence controlled (multi)block copolymers have been prepared by SET-LRP and their
binding to human C-type lectin (CTL) DC-SIGN has been reported.[108] The architecture has
been varied by the synthesis of star polymers[109] or through preparation of glycopolymer
nanoparticles; either polymeric nanoparticles[27] from self-assembly in solution or inorganic-
polymer hybrid particles from the grafting of glycopolymers to, or from, the surface of
inorganic nanoparticles such as iron oxide.[110, 111] In both cases non-covalent interactions with
plant lectin ConA have been exemplified in polymer-lectin clustering experiments and
turbidimetry.
The use of non-covalent interactions is becoming a viable alternative to covalent protein/peptide
modification owing to the potential for temporal control over the conjugate integrity. The ideal
system would benefit from high enough affinity to form a stable protein-polymer conjugate, but
obviate any detrimental effects on bioactivity by facilitating release of the native protein in the
presence of an appropriate competitive ligands.
4. Applications of protein/peptide polymer conjugates
4.1. Improving the ‘shelf-life’ of Oxytocin
Oxytocin is a versatile therapeutic neuropeptide, administered to treat a variety of physiological
and psychological conditions. The World Health Organisation (WHO) list oxytocin as an
essential medicine, primarily for its use as an agonist for uterine contraction to prevent, or treat,
postpartum haemorrhaging (PPH) after delivery. Maternal mortality rates are generally low and
continue to improve in developed nations. In stark contrast, mortality is unacceptably high in
developing nations, in particular sub-Saharan Africa and South Asia, wherein 99% of
worldwide maternal deaths will occur in 2016.[112] In these, often remote areas, deficiencies in
simple medical resources and infrastructure such as cold chain transportation and storage can
exacerbate complications that arise during pregnancy, delivery and recovery. This is because
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oxytocin is chemically unstable in aqueous solution especially in hot and humid conditions.[113]
Degradation severely diminishes therapeutic efficacy, to a point where it is quite common for
levels of oxytocin, in samples labelled oxytocin, to contain zero active peptide in many
countries where cold chain storage is not available.
A number of strategies for improving aqueous stability or precluding the need for aqueous
solutions of oxytocin are being explored, including; the use of excipients in aqueous
formulation,[114] disulfide bond engineering[115] and peptide-polymer conjugation.[76]
The disulfide bond (Cys1-Cys6) present is complicit in the instability of oxytocin due to its
propensity to undergo dimerization, β-elimination, oxidation and polysulfide formation.[113] It
is also an attractive site for modification with polymers containing disulfide reactive end-groups
such DSM or arsenic. Using a DTM functional initiator, the conditions of aqueous SET-LRP
were adapted to furnish DTM-functional POEGA of increasing molecular weight (DPn = 20,
50, 100; Mn = 12, 31, 56 kDa; Ɖ < 1.36). Upon addition of the crude polymer to reduced
oxytocin, direct from the reaction mixture, conjugates of increasing molecular weight and size
were formed. The effect of polymer conjugation on the stability of oxytocin was assessed via
an accelerated stability assay, performed at 50 °C. The native oxytocin was shown to completely
degrade over a period of 28 days, whereas the oxytocin-POEGA conjugates retained > 90%
integrity over the same time period (Figure 8).[76]
Insert figure 8 here
Alternatively, the N-terminus was targeted for modification with linear PEG and comb
polymers of OEG(M)A and oligo(2-ethyl-2-oxazoline) methacrylate (OEtOxMA) through
NHS-ester and aldehyde (CHO) functional end-groups from which both irreversible and
reversible conjugates could be formed.[116, 117] Comb polymers were synthesized from
functional initiators using either Cu0-wire mediated polymerization (NHS-POEGA, CHO-
POEGA) or aqueous SET-LRP (CHO-POEGMA, CHO-P(OEtOxMA). Accelerated stability
assays again demonstrated enhanced stability for oxytocin-polymer conjugates compared to
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native oxytocin and oxytocin in the presence of unconjugated polymers, which proved that the
stability enhancement was an effect of covalent conjugation as opposed to an excipient effect
(Figure 8). Comb polymers were found to improve stability relative to linear analogues,
however linear polymers granted improved release of the oxytocin from the conjugate as a
function of pH, which could prove crucial from a bioactivity point of view.
The preparation of oxytocin-polymer conjugates has been shown to markedly improve the
stability of the peptide in aqueous solution. Furthermore, the simple and dynamic chemistry
employed is opportunistic for retaining bioactivity, which, along with tuning the local
environment of the conjugate-linker, is currently being investigated.
4.2. Topical delivery of Polymyxins
Prophylactic and responsive administration of antibiotics is routine medical/surgical practice
for the prevention and treatment of bacterial infections. Despite this, sepsis, the body’s
inflammatory response to infection by bacterial pathogens, is a major killer worldwide.
Infections by multidrug-resistant (MDR) bacterial pathogens, such as Gram-negative
‘superbugs’ Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae
are a major global healthcare burden. This is augmented by the lack of any novel antibiotic
development over the last 30 years, and an increasing number of reports regarding new cases
of resistance against the polymyxin family of antibiotics. Thus, there is an urgent need for new
antimicrobials and/or improved antimicrobial therapies.
Open wounds such as those presented by severe burns, are particularly susceptible to ‘superbug’
infections due to the disruption of the epidermal barrier, the systemic apoptotic response and
immunosuppression that disrupts self-defense mechanisms to fight infection.[118] Therefore, the
use of topical antimicrobial chemotherapy has been fundamental and helped to improve the
management and survival of patients with major burns by minimising the incidence of life-
threatening burn wound sepsis.[119]
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Polymyxins B and Polymyxin E (colistin)[120] are administered clinically for treatment of MDR
gram-negative bacterial infections. The lipopeptide can bind to lipopolysaccharide (LPS) in the
bacterial outer membrane, altering the permeability leading to cell death.[121] As a small and
highly charged lipopeptide, colistin is subject to rapid renal clearance and incidence of
nephrotoxicity[122] under systemic administrations. Considering this, and its high degree of
functionality (5 amines from 2,4-diamino butyric acid residues) it was identified as a candidate
for hydrogel-based topical delivery, using a simple, dynamic imine-based hydrogel system
composed of amine-functional chitosan glycol and a bis-aldehyde functional linear PEG cross-
linker (Figure 9).[123]
Insert figure 9 here
Although colistin contains five amine groups, alone it was not capable of forming a gel with
the PEG crosslinker. However, in the presence of chitosan glycol, dynamic gels were formed,
the integrity of which was unaffected by the presence of the colistin at concentrations between
25-250 mg.L-1. Successful encapsulation was first demonstrated by washing the colistin-loaded
hydrogels with water, samples of which were shown to contain no colistin. Release assays were
performed in both PBS and cation-adjusted Mueller–Hinton (CAMHB) bacterial growth media,
in which colistin was steadily released over a period of 24 hrs. Furthermore, the activity of the
colistin-loaded hydrogels was comparable to equivalent concentrations of colistin in solution,
in the absence of the gel matrix, and correlated well with the release kinetics in both in vitro
assays (disk diffusion, time-kill) and an in vivo animal burn model.[124] Implications of this on
viable dose regimens and nephrotoxicity in this system and in systemic delivery systems
currently being developed are under investigation.
5. Conclusion
The ability to control molecular composition and architecture using RDRP has brought us closer
than ever to the sophistication and complexity of nature and naturally occurring
macromolecules. The development of aqueous SET-LRP has expanded the monomer
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compatibility of Cu-mediated polymerization and enables polymerization to take place not only
in pure aqueous media but also in biologically relevant media such as PBS and blood serum.
Careful manipulation of the reaction conditions can also facilitate the formation of (multi)block
copolymers which, in the case of responsive double hydrophilic block copolymers, can form
higher-order structures under stimulus. This technique, and others, has been applied to the
synthesis of polymers with high α-end group fidelity, the functionality of which is predisposed
for reaction with proteins/peptides. The functionality presented by proteins/peptides offers
wealth of opportunity for chemical modification, often at the expense of site-selectivity and
specificity. Using DSM and arsenical-functional polymers, conjugation to peptides can now be
achieved rapidly, and stoichiometrically by re-bridging reduced disulfide bonds. The relatively
low natural abundance of the cysteine, and the accessibility of disulfides render this approach
highly specific, which is enhanced further by the use of arsenicals that react with disulfides with
unrivalled specificity, even in the presence of free cysteine residues. Using these techniques,
and others, peptide-polymer conjugates of therapeutic relevance (oxytocin, colistin) have been
prepared and exhibit advantageous properties such as enhanced stability and controlled release.
There is great potential in the combination of bioactive (macro)molecules with polymers, either
covalently through conjugation or non-covalently using hydrogels or higher-order self-
assembled structures, to address challenging biomedical problems, which is the working vision
of my fledgling laboratory.
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Figure 1. Recent advances in Cu-mediated polymerization allow polymerization to proceed in
biological media[31] and under the influence external stimulus.[22]
Reproduced with permission.[31] 2013, Royal Society of Chemistry.
Reproduced with permission.[22] 2014, American Chemical Society.
A B
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Figure 2. Rapid and complete disproportionation of CuIBr/Me6-Tren exploited for the
polymerization of NIPAM in pure aqueous media. The first example of aqueous SET-LRP.
Adapted with permission.[24] 2013, American Chemical Society.
Figure 3. Synthesis and aggregation of double hydrophilic diblock copolymers prepared by
aqueous SET-LRP via in situ sequential monomer addition.
Adapted with permission.[27] 2014, American Chemical Society.
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Figure 4. Site-specific protein/peptide conjugation targeting disulfides. The conjugation of
DSM and arsenicals is highlighted for further discussion.
Figure 5. Conjugation-induced fluorescence occurs during the rapid and stoichiometric
conjugation of DSM reagents to reduced disulfides.
Adapted with permission.[72] 2013, American Chemical Society.
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Figure 6. Organic arsenicals as highly efficient linkers in protein/polymer conjugation with
unrivalled site-specificity for disulfide bond derived dithiols, in the presence of mono-thiols.
Adapted with permission.[78] 2015, American Chemical Society.
Figure 7. Organic arsenicals as highly efficient linkers in protein/polymer conjugation with
unrivalled site-specificity for disulfide bond derived dithiols, in the presence of mono-thiols.
Adapted with permission.[92] 2015, American Chemical Society.
- 29 -
Figure 8. The stability of oxytocin is enhanced by polymer conjugation at both the disulfide
bond and N-terminal amine.
Adapted with permission.[76, 116] 2015/2016, American Chemical Society.
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Figure 9. Schematic for the formation of colistin-loaded hydrogels which show efficient release
and comparable activity to colistin in solution.
Adapted with permission.[124] 2016, Wiley VCH.
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State of the art RDRP and protein/peptide modification methods, have brought synthetic
polymer and materials science closer than ever to replicating the precision of nature. The
development of aqueous SET-LRP and efficient, highly specific disulfide targeted
modifications, using organic arsenicals, furnishes protein-polymer conjugates with unrivalled
precision. Continued progress is crucial considering the clear benefits associated with attaching
polymers to therapeutic peptides such as oxytocin and polymyxins.
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